Definitive Contract HHSN272201600009C
Award Date
3/22/16
Potential Completion Date
9/8/21
Potential Value
$6.8M
Federal Agency
National Institute of Allergy and Infectious Diseases
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Alachua, FL 32615, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
29
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a cost-plus-fixed-fee Delivery Order awarded by the Joint Program Executive Office for Chemical and Biological Defense, a component of the U.S. Department of the Army, to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.). The $107,935,344 award supports the clinical development of an FDA-licensed monoclonal antibody countermeasure for exposure to botulinum neurotoxin. The work will involve tasks such as clinical trials, process development, and...
This is a prime contract award to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.) by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services. The $14,898,362.53 cost-plus-fixed-fee contract is for biomedical research and development. It has a period of performance through December 31, 2011 and does not have a set-aside designation. Resilience Government Services is a technology-focused...
This is a $3,044,549.00 fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.). The contract is for biomedical research and development work, with a period of performance ending on March 31, 2010. No set-aside designations were used. Resilience Government Services, a technology-focused biomanufacturing company, has...
This is a definitive contract awarded by the Department of the Army's Joint PEO Chemical and Biological Defense, a defense agency, to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.). The $366,290,602.35 cost-plus-fixed-fee contract is for the Medical Countermeasures Advanced Development and Manufacturing (MCM ADM) Capability, with a period of performance through October 31, 2023. As a prime contractor, Resilience has provided a range of goods and services related...
This is a $799,780 cost-plus-fixed-fee delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.). The contract is for the development of analytical methods, upstream and downstream manufacturing processes, scale-up production, and release testing for the LNA14 product. This delivery order falls under a larger...
This is a $16,413,163.00 Cost Plus Fixed Fee contract awarded by the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc., a biotechnology company specializing in antibody-based therapeutics and medical countermeasures against infectious diseases and biothreats. The contract is for the development of a pan-botulinum neurotoxin medical countermeasure, with a period of performance ending on June 30,...
This federal contract award to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.) is valued at $9,080,310.52 and was issued by the Joint PEO Chemical and Biological Defense, part of the U.S. Department of the Army. The award is for drug substance process validation, drug product process validation, clinical development phase 3, and storage/stability activities to support the U.S. FDA licensure of the BONT MAB G03-52-01 drug product. The contract was awarded on March...
The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a $5,107,357.36 Other Transaction Agreement to Resilience Government Services, Inc., doing business as Nanotherapeutics Inc., a technology-focused biomanufacturing company. The contract, which has no set-aside designation, is for the development of a "Plasmid Platform Protype" and is part of a larger $5.7 million Indefinite Delivery Vehicle aimed at transferring capabilities to...
<p>This is a $205,003,103.62 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Modex Therapeutics, Inc. to advance the development of potent, cross-reactive multispecific antibodies for the preparedness countermeasure of COVID-19 and seasonal and highly pathogenic avian influenza. The contract has an ultimate completion date of January 18, 2030. This award is not a set-aside contract.</p>
This is a federal contract award from the Office of the Assistant Secretary for Preparedness and Response (part of the U.S. Department of Health and Human Services) to Battelle Memorial Institute, a large nonprofit research and development organization, for $5,915,273.00 to provide testing services to support the development of next-generation botulism therapeutic products. The contract is a cost-plus-fixed-fee Delivery Order, with an ultimate completion date of April 5, 2027. It is not...